9 completed, 1 terminated. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Terminated 1 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow AS03 adjuvant: new trials by email Literature Review of AS03 adjuvant trials Research Report on AS03 adjuvant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19） MT-2766 High dose (3.75 µg), Placebo, MT-2766 Low dose - SARS-CoV-2 Infection | Phase 1 / Phase 2 | Terminated | Medicago | 128 | 2021-10-02 | 2023-11-07 |
| A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3 - Influenza, Human | Phase 2 | Completed | GlaxoSmithKline | 833 | 2021-03-16 | 2023-10-10 |
| SCB-2019 as COVID-19 Vaccine SCB-2019, SCB-2019 with AS03 adjuvant, SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant - COVID-19 | Phase 1 | Completed | Clover Biopharmaceuticals AUS Pty | 166 | 2020-06-19 | 2022-02-18 |
| Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59 VN, IN, dk/BANG - Influenza A Virus, H5N1 Subtype | Phase 2 | Completed | Biomedical Advanced Research and Development Authority | 720 | 2018-03-15 | 2020-07-14 |
| Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV - Influenza, Vaccine | Phase 1 | Completed | PATH | 65 | 2017-10-10 | 2021-02-21 |
| Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant H7N9 pLAIV, H7N9 pIIV, AS03 adjuvant - Influenza A Virus, H7N9 Subtype | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 53 | 2016-12-01 | 2018-10-02 |
| Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03) H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant - Influenza A Virus, H5N1 Subtype | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2013-07-01 | 2019-02-12 |
| H5N1 Vaccination With and Without AS03: Systems Biology Analysis ASO3 Adjuvant, Influenza A/H5N1 Vaccine - Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2012-05-24 | 2019-10-21 |
| Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant - Influenza | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 43 | 2012-03-20 | 2019-02-26 |
| H5N1 Mix and Match With AS03 AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen - Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 245 | 2011-05-01 | 2013-01-18 |
Influenza, Human (5) · Influenza in Birds (4) · COVID-19 (2) · Virus Diseases (1)
National Institute of Allergy and Infectious Diseases (NIAID) (5) · Biomedical Advanced Research and Development Authority (1) · Clover Biopharmaceuticals AUS Pty (1) · GlaxoSmithKline (1) · Medicago (1) · PATH (1)
United States (8) · Australia (1) · Japan (1)
Angela Branche (1) · David Bernstein, MD (1) · Jeffrey Guptill, MD (1) · John S Tsang, Ph.D. (1) · Nadine Rouphael, MD (1)
PMID 25734159, PMID 28099485, PMID 30302282, PMID 31630990, PMID 33288923, PMID 33524311, PMID 34174187, PMID 36533948, PMID 38181048, PMID 39702896, PMID 40132593
U19AI090023 (1)